Beam Therapeutics Share Price (NASDAQ: BEAM)

$16.61

▲

-0.49

(-2.87%)

Live

Last updated on August 20, 2025 at 12:38 AM IST

$₹

Check the interactive Beam Therapeutics Stock chart to analyse performance

Beam Therapeutics stock performance

as on August 20, 2025 at 12:38 AM IST

Today's Low:$16.45
Today's High:$17.00
$16.61
0.96%
Downside
Day's Volatility :3.24%
Upside
2.29%
52 Weeks Low:$13.53
52 Weeks High:$35.25
$16.61
18.57%
Downside
52 Weeks Volatility :61.63%
Upside
52.88%

Beam Therapeutics Stock Returns

Period	Beam Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-3.69%	1.1%	0.0%
6 Months	-48.95%	-7.2%	0.0%
1 Year	-31.62%	-11.6%	0.0%
3 Years	-66.75%	2.2%	-9.6%

Beam Therapeutics Inc Key Stats

Check Beam Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$17.1
Open	$17.89
Today's High	$17.0
Today's Low	$16.38
Market Capitalization	$1.8B
Today's Volume	$2.7M
52 Week High	$35.25
52 Week Low	$13.525
Revenue TTM	$60.3M
EBITDA	$-424.0M
Earnings Per Share (EPS)	$-4.5
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-41.94%

Stock Returns calculator for Beam Therapeutics Stock including INR - Dollar returns

The Beam Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Beam Therapeutics investment value today

Current value as on today

₹70,064

Returns

₹29,936

(-29.94%)

Returns from Beam Therapeutics Stock

₹33,560 (-33.56%)

Dollar Returns*

₹3,624 (+3.62%)

Indian investors sentiment towards Beam Therapeutics Stock

90.07%

Period: Jul 19, 2025 to Aug 18, 2025. Change in 30 Days versus previous period

Investment in Beam Therapeutics Shares from India has grown by 90.07% over the past 30 days, indicating increased transactional activity.

76%

Period: Jul 19, 2025 to Aug 18, 2025. Change in 30 Days versus previous period

Search interest for Beam Therapeutics Stock from India on INDmoney has increased by 76% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Beam Therapeutics Inc

Name
Holdings %
Name
Holdings %
Farallon Capital Management, L.L.C.
9.81%
Vanguard Group Inc
9.59%
ARK Investment Management LLC
8.75%
BlackRock Inc
8.01%
FMR Inc
7.83%
Sumitomo Mitsui Trust Group Inc
4.68%

Analyst Recommendation on Beam Therapeutics Stock

Rating

Trend

Buy

61%Buy

38%Hold

0%Sell

Based on 21 Wall street analysts offering stock ratings for Beam Therapeutics(by analysts ranked 0 to 5 stars)

Beam Therapeutics Share Price Target

What analysts predicted

Upside of 176.48%

Target:

$45.92

Current:

$16.61

Beam Therapeutics share price target is $45.92, a slight Upside of 176.48% compared to current price of $16.61 as per analysts' prediction.

Beam Therapeutics Stock Insights

Price Movement
In the last 6 months, BEAM stock has moved down by -49.9%
Increasing Revenue
Revenue is up for the last 2 quarters, 7.47M → 8.46M (in $), with an average increase of 11.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -109.27M → -102.29M (in $), with an average increase of 6.8% per quarter
BEAM vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.4% return, outperforming this stock by 98.0%
BEAM vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 179.4%
Price to Sales
ForBEAM every $1 of sales, investors are willing to pay $25.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.0 for every $1 of sales.

Beam Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$18.0K	-
Net Income	$-78.4M	↓ 31.94%
Net Profit Margin	-435.8K%	-

	FY20	Y/Y Change
Revenue	$24.0K	↑ 33.33%
Net Income	$-256.4M	↑ 226.9%
Net Profit Margin	-1.1M%	↓ 632644.44%

	FY21	Y/Y Change
Revenue	$51.8M	↑ 215916.67%
Net Income	$-341.4M	↑ 33.12%
Net Profit Margin	-658.44%	↑ 1067774.89%

	FY22	Y/Y Change
Revenue	$60.9M	↑ 17.51%
Net Income	$-263.6M	↓ 22.78%
Net Profit Margin	-432.68%	↑ 225.76%

	FY23	Y/Y Change
Revenue	$377.7M	↑ 520.01%
Net Income	$-132.5M	↓ 49.72%
Net Profit Margin	-35.09%	↑ 397.59%

	FY24	Y/Y Change
Revenue	$63.5M	↓ 83.18%
Net Income	$-376.7M	↑ 184.28%
Net Profit Margin	-593.13%	↓ 558.04%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$7.4M	↓ 97.66%
Net Income	$-98.7M	↓ 169.1%
Net Profit Margin	-1.3K%	↓ 1376.73%

	Q2 FY24	Q/Q Change
Revenue	$11.8M	↑ 58.87%
Net Income	$-91.1M	↓ 7.72%
Net Profit Margin	-773.45%	↑ 558.12%

	Q3 FY24	Q/Q Change
Revenue	$14.3M	↑ 21.21%
Net Income	$-96.7M	↑ 6.17%
Net Profit Margin	-677.47%	↑ 95.98%

	Q4 FY24	Q/Q Change
Revenue	$30.1M	↑ 110.72%
Net Income	$-90.4M	↓ 6.53%
Net Profit Margin	-300.51%	↑ 376.96%

	Q1 FY25	Q/Q Change
Revenue	$7.5M	↓ 75.16%
Net Income	$-109.3M	↑ 20.94%
Net Profit Margin	-1.5K%	↓ 1162.27%

	Q2 FY25	Q/Q Change
Revenue	$8.5M	↑ 13.33%
Net Income	$-102.3M	↓ 6.39%
Net Profit Margin	-1.2K%	↑ 254.52%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-5.4M	↑ 729.08%

	FY20	Y/Y Change
Profit	$-103.2M	↑ 1814.18%

	FY21	Y/Y Change
Profit	$35.4M	↓ 134.32%

	FY22	Y/Y Change
Profit	$38.3M	↑ 8.3%

	FY23	Y/Y Change
Profit	$-59.7M	↓ 255.63%

	FY24	Y/Y Change
Profit	$63.5M	↓ 206.45%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$2.0M	↓ 99.36%

	Q2 FY24	Q/Q Change
Profit	$6.2M	↑ 213.09%

	Q3 FY24	Q/Q Change
Profit	$8.8M	↑ 41.93%

	Q4 FY24	Q/Q Change
Profit	$-17.0M	↓ 292.96%

	Q1 FY25	Q/Q Change
Profit	$7.5M	↓ 144.02%

	Q2 FY25	Q/Q Change
Profit	$2.9M	↓ 60.8%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-72.0M	↑ 254.73%
Investing Cash Flow	$-66.7M	↑ 396.57%
Financing Cash Flow	$41.3M	↓ 77.03%

	FY20	Y/Y Change
Operating Cash Flow	$-95.7M	↑ 32.97%
Investing Cash Flow	$-100.1M	↑ 50.2%
Financing Cash Flow	$322.3M	↑ 680.84%

	FY21	Y/Y Change
Operating Cash Flow	$-66.3M	↓ 30.78%
Investing Cash Flow	$-294.1M	↑ 193.78%
Financing Cash Flow	$756.1M	↑ 134.59%

	FY22	Y/Y Change
Operating Cash Flow	$22.5M	↓ 133.99%
Investing Cash Flow	$-461.3M	↑ 56.84%
Financing Cash Flow	$111.6M	↓ 85.24%

	FY23	Y/Y Change
Operating Cash Flow	$-149.2M	↓ 762.29%
Investing Cash Flow	$71.8M	↓ 115.57%
Financing Cash Flow	$276.4M	↑ 147.74%

	FY24	Y/Y Change
Operating Cash Flow	$-347.2M	↑ 132.75%
Investing Cash Flow	$185.0M	↑ 157.53%
Financing Cash Flow	$7.7M	↓ 97.2%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-99.7M	↓ 173.85%
Investing Cash Flow	$-53.5M	↓ 154.5%
Financing Cash Flow	$2.9M	↓ 91.41%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-83.0M	↓ 16.78%
Investing Cash Flow	$87.5M	↓ 263.65%
Financing Cash Flow	$133.0K	↓ 95.41%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-88.1M	↑ 6.16%
Investing Cash Flow	$24.7M	↓ 71.77%
Financing Cash Flow	$1.3M	↑ 848.87%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-76.4M	↓ 13.34%
Investing Cash Flow	$126.3M	↑ 411.3%
Financing Cash Flow	$3.4M	↑ 172.9%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-103.9M	↑ 36.04%
Investing Cash Flow	$-125.1M	↓ 199.06%
Financing Cash Flow	$473.4M	↑ 13645.03%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-76.5M	↓ 26.41%
Investing Cash Flow	$-170.4M	↑ 36.23%
Financing Cash Flow	$1.1M	↓ 99.77%

Beam Therapeutics Technicals Summary

Sell

Neutral

Buy

Beam Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Beam Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Beam Therapeutics Inc	-18.71%	-48.95%	-31.62%	-66.75%	-78.01%
Regeneron Pharmaceuticals, Inc.	5.3%	-15.53%	-52.01%	-6.15%	-6.88%
Beone Medicines Ltd	9.32%	34.03%	65.78%	84.48%	35.61%
Vertex Pharmaceuticals Incorporated	-14.97%	-15.63%	-20.12%	32.68%	43.64%
Alnylam Pharmaceuticals, Inc.	42.53%	82.74%	66.44%	109.65%	235.02%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Beam Therapeutics Inc	NA	NA	NA	-4.3	-0.42	-0.21	NA	10.7
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Beam Therapeutics Inc	Buy	$1.8B	-78.01%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-6.88%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	35.61%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	43.64%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	235.02%	NA	-12.96%

Beam Therapeutics Dividend announcements

Beam Therapeutics Earnings
Beam Therapeutics’s price-to-earnings ratio stands at None

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Organization	Beam Therapeutics
Employees	509
CEO	Mr. John M. Evans M.B.A.
Industry	Health Technology

Key Management of Beam Therapeutics Inc

Name	Title
Mr. John M. Evans M.B.A.	CEO & Director
Dr. Giuseppe Ciaramella Ph.D.	President
Mr. Sravan Kumar Emany	Chief Financial Officer
Dr. Christine P. Bellon J.D., Ph.D.	Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Amy Simon M.D.	Chief Medical Officer
Dr. Feng Zhang Ph.D.	Co-Founder
Dr. David R. Liu Ph.D.	Co-Founder
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder
Dr. Manmohan Singh Ph.D.	Chief Technology Officer
Dr. Gopi Shanker Ph.D.	Chief Scientific Officer

Important FAQs about investing in BEAM Stock from India :

What is Beam Therapeutics share price today?

Beam Therapeutics share price today is $16.61 as on August 20, 2025 at 12:38 AM IST. Beam Therapeutics share today touched a day high of $17.00 and a low of $16.45.

What is the 52 week high and 52 week low for Beam Therapeutics share?

Beam Therapeutics share touched a 52 week high of $35.25 and a 52 week low of $13.53. Beam Therapeutics stock price today i.e. August 20, 2025 at 12:38 AM IST is trending at $16.61, lower by 52.88% versus the 52 week high.

How to invest in Beam Therapeutics Stock (BEAM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Beam Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Beam Therapeutics Shares that will get you 0.0903 shares as per Beam Therapeutics share price of $16.61 per share as on August 20, 2025 at 12:38 AM IST.

What is the minimum amount required to buy Beam Therapeutics Stock (BEAM) from India?

Indian investors can start investing in Beam Therapeutics (BEAM) shares with as little as ₹86.938 or $1 (as of August 19, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹869.38 in Beam Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 19, 2025). Based on Beam Therapeutics share’s latest price of $16.61 as on August 20, 2025 at 12:38 AM IST, you will get 0.6020 shares of Beam Therapeutics. Learn more about fractional shares .

What are the returns that Beam Therapeutics has given to Indian investors in the last 5 years?

Beam Therapeutics stock has given -78.01% share price returns and 16.15% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?